Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study
Romy N. Bouwmeester*, Caroline Duineveld, Kioa L. Wijnsma, Frederike J. Bemelman, Joost W. van der Heijden, Joanna A.E. van Wijk, Antonia H.M. Bouts, Jacqueline van de Wetering, Eiske Dorresteijn, Stefan P. Berger, Valentina Gracchi, Arjan D. van Zuilen, Mandy G. Keijzer-Veen, Aiko P.J. de Vries, Roos W.G. van Rooij, Flore A.P.T. Engels, Wim Altena, Renée de Wildt, Evy van Kempen, Eddy M. AdangMendy ter Avest, Rob ter Heine, Elena B. Volokhina, Lambertus P.W.J. van den Heuvel, Jack F.M. Wetzels, Nicole C.A.J. van de Kar
Research output: Contribution to journal › Article › Academic › peer-review
2Citations
(Scopus)
6Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study'. Together they form a unique fingerprint.